Clinical Data Disclosure Embraced By Pharma; Now It Needs Partners
Pfizer has not received many requests for its data and wants to find ways to encourage researchers to make the most use of available data; AstraZeneca’s Gregory Curt says the sharing of trial results eventually could eliminate the need for comparator arms.
You may also be interested in...
ClinicalTrials.gov Still Lacks Many Study Results, JAMA Finds; Do Transparency Efforts Need A Boost?
Industry data transparency initiatives are well-established now, but JAMA study suggests holes in efforts to publicly release clinical trial results.
In what appears to be the most expansive policy to date on release of clinical trial data, J&J will use an existing outside group and will share full clinical study reports and patient-level data regardless of when the studies were conducted.
Senators ask the agency to address the “regulatory loophole” permitting telehealth companies to promote prescription drugs without disclosing side effects and question if FDA has enforcement authority over third-party social media influencer promotions.